Clara N Curiel

Clara N Curiel

Director, Cutaneous Oncology Program
Division Chief, Dermatology
Member of the Graduate Faculty
Professor, BIO5 Institute
Professor, Medicine - (Tenure Track)
Primary Department
Department Affiliations
Contact
(520) 626-0307

Research Interest

Clara Curiel-Lewandroski, PhD, is the director of the Pigmented Lesion Clinic and Multidisciplinary Cutaneous Oncology Program, both part of the University of Arizona Cancer Center Skin Cancer Institute. She completed two research fellowships, the first in the Department of Dermatology at Harvard Medical School, and the second at the Ludwig Boltzman Institute and Immunobiology of the Skin at Miinster University in Germany. Dr. Curiel is certified by the American Board of Dermatology.Dr. Curiel-Lewandroski’s research focus is on melanoma chemoprevention, early detection of melanoma, cutaneous T cell lymphomas and skin cancer. She studied the extended use of non-steroidal anti-inflammatory drugs, particularly aspirin, and their ability to possibly decrease the risk of cutaneous medanoma (CM) development. CM is responsible for more than 77 percent of skin cancer deaths.

Publications

Kim, C. C., Kim, E. J., Curiel-Lewandrowski, C., Marks, V., Maloney, M., & Frieden, I. J. (2013). A model in dermatology for long-distance mentoring. Journal of the American Academy of Dermatology, 68(5), 860-2.
Kittler, H., Marghoob, A. A., Argenziano, G., Carrera, C., & Curiel-Lewandrowski, C. N. (2016). Standardization of Terminology in Dermoscopy/Dermatoscopy: 1 Results of the 3rd Consensus Conference. J Am Acad Dermatol.
Curiel-Lewandrowski, C., Kim, C. C., Swetter, S. M., Chen, S. C., Halpern, A. C., Kirkwood, J. M., Leachman, S. A., Marghoob, A. A., Ming, M. E., Grichnik, J. M., & , M. P. (2012). Survival is not the only valuable end point in melanoma screening. The Journal of investigative dermatology, 132(5), 1332-7.
Curiel, R., Perez-Gonzalez, J. F., Brito, N., Zerpa, R., & Curiel, C. N. (1989). Positive inotropic effect mediated by alpha-1 adrenoceptor in intact human subjects. J Cardiovasc Pharmacol, 61(4), 603-615.
Arzberger, E., Curiel-Lewandrowski, C., Blum, A., Chubisov, D., Oakley, A., Rademaker, M., Soyer, H., & Hofmann-Wellenhof, R. (2016). Teledermoscopy in High-risk Melanoma Patients: A Comparative Study of Face-to-face and Teledermatology Visits. Acta dermato-venereologica.

Teledermoscopy is considered a reliable tool for the evaluation of pigmented skin lesions. We compared the management decision in face-to-face visits vs. teledermatology in a high-risk melanoma cohort using total-body photography, macroscopic and dermoscopic images of single lesions. Patients were assessed both face-to face and by 4 remote teledermatologists. Lesions identified as suspicious for skin cancer by face-to-face evaluation underwent surgical excision. The teledermatologists recommended "self-monitoring", "short-term monitoring", or "excision". A 4-year monitoring was completed in a cohort of participating subjects. The general agreement, calculated by prevalence and bias-adjusted κ (PABAK), showed almost perfect agreement (PABAK 0.9-0.982). A total of 23 lesions were excised; all teledermatologists identified the 9 melanomas. The greatest discrepancy was detected in "short-term monitoring". During 4-year monitoring one melanoma was excised that had been considered benign. In conclusion, melanoma identification by experts in pigmented lesions appears to be equivalent between face-to-face and teledermatological consultation.